Methods and materials for identifying and treating membranous nephropathy
US-2024353404-A1 · Oct 24, 2024 · US
Compositions and methods for targeting stromal cells for the treatment of cancer
US10329355B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10329355-B2 |
| Application number | US-201615158727-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 19, 2016 |
| Priority date | Oct 1, 2012 |
| Publication date | Jun 25, 2019 |
| Grant date | Jun 25, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated chimeric antigen receptor (CAR) comprising an antigen binding domain encoded by a nucleic acid sequence comprising SEQ ID NO: 3, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the antigen binding domain binds to a stromal cell antigen. 2. The isolated CAR of claim 1 , wherein the stromal cell antigen is expressed on a stromal cell present in a tumor microenvironment. 3. The isolated CAR of claim 2 , wherein the tumor is a carcinoma. 4. The isolated CAR of claim 1 , wherein the stromal cell antigen is fibroblast activation protein (FAP). 5. The isolated CAR of claim 1 , wherein the costimulatory signaling region comprises the intracellular domain of a costimulatory molecule selected from the group consisting of CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, and any combination thereof. 6. The isolated CAR of claim 1 , wherein the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO: 1. 7. The isolated CAR of claim 1 , wherein the transmembrane domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 5. 8. The isolated CAR of claim 1 , wherein the costimulatory signaling region is encoded by a nucleic acid sequence comprising SEQ ID NO: 6. 9. The isolated CAR of claim 1 , wherein the CD3 zeta signaling domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 7.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
CD8 · CPC title
containing a transmembrane segment · CPC title
containing a signal sequence · CPC title
NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10329355B2 cover?
- The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain…
- Who is the assignee on this patent?
- Univ Pennsylvania, Wistar Inst
- What technology area does this patent fall under?
- Primary CPC classification C07K16/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).